No abstract available
MeSH terms
-
Adenocarcinoma / drug therapy
-
Adenocarcinoma / secondary
-
Adenocarcinoma / surgery
-
Adenocarcinoma / therapy*
-
Antibodies, Bispecific / administration & dosage
-
Antibodies, Bispecific / adverse effects*
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
-
Carcinoma / diagnosis*
-
Chemotherapy, Adjuvant
-
Clinical Trials, Phase II as Topic
-
Diagnosis, Differential
-
Gastrectomy
-
Humans
-
Infusions, Intravenous
-
Infusions, Parenteral
-
Intraoperative Period
-
Male
-
Middle Aged
-
Neoplasm Staging
-
Peritoneal Neoplasms / diagnosis*
-
Peritoneal Neoplasms / secondary
-
Peritonitis / chemically induced
-
Peritonitis / diagnosis*
-
Postoperative Period
-
Stomach Neoplasms / drug therapy
-
Stomach Neoplasms / pathology
-
Stomach Neoplasms / surgery
-
Stomach Neoplasms / therapy*
-
Tomography, X-Ray Computed
-
Treatment Outcome
Substances
-
Antibodies, Bispecific
-
catumaxomab